ライフサイエンスコーパス: breast milk

1 n not to affect their total concentration in breast milk.

2 vestigated dietary effects on fatty acids in breast milk.

3 half by postnatal HIV exposure via maternal breast milk.

4 spectrum of other nutritional properties of breast milk.

5 s were exposed to consistent drug dosing via breast milk.

6 sychoactive drugs, and major metabolites, in breast milk.

7 otentially attributed to anti-HIV factors in breast milk.

8 ission is likely due to antiviral factors in breast milk.

9 ory mechanism for maintaining the quality of breast milk.

10 V and the role of malaria in EBV shedding in breast milk.

11 als were comparable to those in mature human breast milk.

12 ted the presence of major foods allergens in breast milk.

13 hreshold for exposure to maternal drugs from breast milk.

14 of HIV-positive women the health benefits of breast milk.

15 res not only production but also ejection of breast milk.

16 thers are repeatedly exposed to the virus in breast milk.

17 ilk versus formula indicated a faster GE for breast milk.

18 nfidence interval, 18.8%-59.4%) infected via breast milk.

19 rgen from house dust mite, Der p 1, in human breast milk.

20 of Canadian breastfeeding mothers and their breast milk.

21 tentially decrease the beneficial effects of breast milk.

22 s were associated with CMV in the cervix and breast milk.

23 envelope (Env)-specific humoral responses in breast milk.

24 d result in the preferential uptake of FA in breast milk.

25 remainder acquired through modes other than breast milk.

26 ly dependent on the supply of vitamin D from breast milk.

27 OS) to exert similar effects to those of the breast milk.

28 et influences the nutritional composition of breast milk.

29 ions occurred among infants fed CMV-positive breast milk (12-week incidence, 15.3%; 95% CI, 9.3%-20.2

30 (101 days), cerebrospinal fluid (9 months), breast milk (16 months [preliminary data]), and semen (1

31 d as breast milk: median (IQR) proportion of breast milk, 92% (79%-98%) in the lower-protein group vs

32 ble CMV DNA in cervical secretions (66%) and breast milk (99%).

33 ty of the three methods to detect changes in breast milk after storage.

34 These data show that consumption of most breast milk analysed would not result in children exceed

35 n (SD) of 27.7% (15.2%) of the bacteria from breast milk and 10.3% (6.0%) from areolar skin.

36 consumption and high docosahexaenoic acid in breast milk and 2 studies that reported a positive corre

37 The method was validated in breast milk and also in various types of bovine milk, as

38 he association between exposure to PBDEs via breast milk and anthropometric measurements in early chi

39 ations between early-life PBDE exposures via breast milk and anthropometric measurements overall; how

40 termine the association between the maternal breast milk and areolar skin and infant gut bacterial co

41 was used to estimate the contribution of the breast milk and areolar skin microbiomes to the infant g

42 stnatal CMV infection in this population are breast milk and blood transfusion.

43 and its receptor ErbB4 are present in human breast milk and developing human intestine, respectively

44 We estimated the relative contributions of breast milk and formula to arsenic exposure during early

45 models to estimate daily arsenic intake from breast milk and formula.

46 eration given to combination feeding of both breast milk and formula.

47 the partitioning of PBDEs between serum and breast milk and how this may affect infant exposure.

48 al IgG and OVA immune complexes (IgG-IC) via breast milk and induction of allergen-specific regulator

49 l IgA reduces risk of HIV-1 transmission via breast milk and into immune interventions aimed at enhan

50 al transfer of lead from maternal blood into breast milk and its contribution to infant lead burden r

51 iciency alters TRAIL protein levels in human breast milk and mammary epithelial cells.

52 We compared the HIV-1 envelope-specific breast milk and plasma antibody responses of clade C HIV

53 While the envelope-specific breast milk and plasma IgA responses also did not reach

54 eding women, the estimated infant doses from breast milk and resultant infant plasma concentrations f

55 s but could detect EBV-2 in samples of their breast milk and saliva.

56 revealed persisting EBOV RNA in the mother's breast milk and the father's seminal fluid.

57 yze the passage of peanut allergens in human breast milk and their allergenicity/immunomodulatory pro

58 enofovir and emtricitabine are excreted into breast milk and then absorbed by the breastfeeding infan

59 etabolites were detected between infants fed breast milk and those fed formula (P < 0.005) and betwee

60 Infants receiving only breast milk and those with introduction of other foods b

61 What lactating mothers eat flavors breast milk and, in turn, modifies their infants' accept

62 determine the total antioxidant capacity of breast milks and the results were compared with a common

63 Breast-milk and infant measures were obtained at 1 and 6

64 nfected inocula, such as genital secretions, breast milk, and blood, contain both cell-free virus and

65 and DDE were measured in maternal serum and breast milk, and children's weight, height, and waist ci

66 antioxidant found in soil, enriched in human breast milk, and essential for development in mammals.

67 efavirenz concentrations in maternal plasma, breast milk, and infant plasma (n = 134).

68 PFASs occur in breast milk, and the duration of breastfeeding is associ

69 ms protect their pups from infection through breast milk antibodies to investigate innate immune resp

70 turated fatty acids (PUFAs) and n-6 PUFAs in breast milk are associated with the development of aller

71 s indicate that concentrations of arsenic in breast milk are relatively low even in areas with high d

72 al for the maintenance of nutrient status in breast milk are unclear.

73 Bacterial composition in maternal breast milk, areolar skin, and infant stool by sequencin

74 sequencing of the 16S ribosomal RNA gene in breast milk, areolar skin, and infant stool samples of 1

75 Incidence and dominance of skin and breast milk associated microbes were increased in the gu

76 m infants who were fed solids in addition to breast milk at 4 mo postpartum achieved both standing [a

77 Whether the vitamin D content of breast milk at birth can be increased by supplementing t

78 d was defined as >80% of feeds consisting of breast milk at both points; formula-fed was defined as >

79 clonal antibodies isolated from Env-specific breast milk B cells demonstrated diverse Env epitope spe

80 as identified between Env-specific blood and breast milk B cells, suggesting trafficking of that cell

81 ormula than for infants fed exclusively with breast milk (beta = 2.02; 95% CI: 1.21, 2.83; p < 0.0001

82 Breast milk (BM) is a biofluid that has a fundamental ro

83 sis of the type and amount of milk consumed: breast milk (BM), <600 mL formula milk/d (FMlow), >/=600

84 ing at the breast (DBF), pumping and feeding breast milk (BM), and formula (FF) in the first months"

85 spite the nutritional and health benefits of breast milk, breast milk can serve as a vector for mothe

86 irus is present in urine, saliva, tears, and breast milk, but the transmission risk associated with t

87 detect the presence of the food allergens in breast milk by microarray technology.

88 en maternal diet and a nutritive property of breast milk came from 3 studies that supported the link

89 We also demonstrate that breast milk can prevent multiple routes of HIV acquisiti

90 nt HIV-inhibitory activity and indicate that breast milk can prevent multiple routes of infection.

91 ritional and health benefits of breast milk, breast milk can serve as a vector for mother-to-child HI

92 ripheral blood mononuclear cells (PBMCs) and breast milk cells (BMCs) is increased for CD8+ T cells i

93 The breast milk CMV level required to attain a 50% probabili

94 Maternal breast milk CMV levels (hazard ratio [HR], 1.4; P = .003

95 Breast milk CMV levels and maternal CD4 count are major

96 Maternal immune reconstitution or lowering breast milk CMV levels may reduce vertical CMV transmiss

97 Approaches that reduce maternal cervical and breast milk CMV reactivation may help delay infant infec

98 fant CMV acquisition; each log10 increase in breast milk CMV was associated with a 40% increase in in

99 -gamma/granzyme rB producers is increased in breast milk compared with PBMCs.

100 n addition, while significant differences in breast milk composition between transmitting and nontran

101 he evidence that variations in colostrum and breast milk composition can influence allergic outcomes

102 romote infant health through modification of breast milk composition.

103 studies that reported a dietary influence on breast-milk composition did not assess diet directly, di

104 for emtricitabine, reflecting trough-to-peak breast milk concentration ratios of 1.0 for tenofovir an

105 We assessed the relationship between breast milk concentrations of five PBDE congeners-BDEs 2

106 Importantly, there was minimal variation in breast milk concentrations of tenofovir and emtricitabin

107 We know that colostrum and breast milk contain a variety of molecules which can inf

108 In this study, we investigated whether breast milk contained infectious EBV and the role of mal

109 Human breast milk containing OVA-IgG-IC induced tolerance in h

110 Breast milk contains a diverse population of bacteria, b

111 Breast milk contains immunoregulatory factors, such as n

112 Our data suggest that breast milk contains infectious EBV and is a potential s

113 Higher infant sTfR (P < 0.01) and breast-milk copper (P < 0.01) predicted increased iron a

114 High EBV load in breast milk correlated with mothers who had Plasmodium f

115 The analysis of allergens presented in breast milk could be a useful tool in allergy prevention

116 g experiments and micronutrient profiling of breast milk demonstrated that the defects observed were

117 icient mice was used to study the effects of breast milk-derived SIgA on development of the gut micro

118 as the presence of bioactive molecules from breast milk dictate gut microbial growth and survival.

119 enz pharmacokinetic parameters in plasma and breast milk differed significantly between patient group

120 nt's jaws, undulation of the tongue, and the breast milk ejection reflex.

121 Breast milk enhances the predominance of Bifidobacterium

122 This study aimed at characterizing breast milk exosomes from human early milk and mature mi

123 Breast milk exposure to HIV accounts for up to 44% of MT

124 eding period is still a limiting factor, and breast milk exposure to HIV accounts for up to 44% of MT

125 The association between breast milk fatty acid composition and asthma, eczema an

126 umeric associations between concentration of breast milk fatty acids and allergic disease outcomes we

127 d feeding method, and the supplementation of breast milk feeding with formula is associated with a mi

128 Blood transfusion and breast milk feeding.

129 OR 1.4, CI 1.3-1.6, p < 0.001), feeding only breast milk for the first 3 d (90% of 7,557 versus 79% o

130 The antibody microarray was incubated with breast milk from 14 women collected from Fundacion Jimen

131 as dietary egg antigen, and can be found in breast milk from diverse regions of the world.

132 present in sera, cervicovaginal lavages, and breast milk from HIV-1-infected individuals.

133 ements (LNSs) on B vitamin concentrations in breast milk from HIV-infected women in Malawi.

134 However, the HIV-inhibitory activity of breast milk from HIV-positive mothers has not been evalu

135 od, saliva, urine, aqueous humor, semen, and breast milk from infected or convalescent patients.

136 urine from 6-week-old infants (n = 72), and breast milk from mothers (n = 9) enrolled in the New Ham

137 Breast milk from mothers of preterm infants was monitore

138 d with a placebo) results in a higher VDA of breast milk >/=2 mo postpartum.

139 weaning, mice that received maternal SIgA in breast milk had a significantly different gut microbiota

140 Breast milk has a faster GE than formula milk.

141 presence of perfluoroalkyl acids (PFAAs) in breast milk has been documented, but their lactational t

142 n risk, the HIV-inhibitory activity of their breast milk has not been compared.

143 Consumption of human breast milk (HBM) attenuates the incidence of necrotizin

144 therefore could potentially protect against breast milk HIV MTCT.

145 ity in HIV-infected infants, or with odds of breast-milk HIV transmission in HIV-exposed infants.

146 In contrast, the magnitudes of the breast milk IgA and secretory IgA responses against HIV-

147 We found that neither plasma nor breast milk IgG antibody responses were associated with

148 energy intake, consumption of LNS may reduce breast milk intake and potentially decrease the benefici

149 In this rural Malawian population, breast milk intake at 9-10 mo of age was not reduced by

150 A subset was randomly selected to estimate breast milk intake at 9-10 mo of age with the dose-to-mo

151 were associated with the proportion of daily breast milk intake in a dose-dependent manner, even afte

152 bjective was to test the hypothesis that the breast milk intake of 9- to 10-mo-old rural Malawian inf

153 The mean (+/- SD) daily breast milk intake of unsupplemented infants was 730 +/-

154 ersely (r = -0.22, P < 0.01) associated with breast milk intake.

155 The present work details the importance of breast milk iron in neonatal development and uncovers an

156 n to providing complete postnatal nutrition, breast milk is a complex biofluid that delivers bioactiv

157 ination to induce anti-HIV immune factors in breast milk is a potential intervention to prevent postn

158 Breast milk is an important determinant of lead burden a

159 The supply of vitamin D from breast milk is limited.

160 The antiviral activity of breast milk is linked to endogenous lipase-dependent gen

161 Breast milk is rich in PUFA, and it has been hypothesize

162 Breast milk is the optimal food for infants, but is also

163 ged with this transfusion approach, maternal breast milk is the primary source of postnatal CMV infec

164 cal CMV detection during pregnancy and later breast milk levels (beta = 0.47; P = .005).

165 for separation and concentration of complex, breast milk-like oligosaccharides from bovine milk indus

166 small amount of iron that is contributed by breast milk, make them iron sufficient until >/=6 mo of

167 It has been hypothesized that n-3 PUFA in breast milk may assist immune and lung development.

168 Our results also suggest multiple factors in breast milk may contribute to its HIV-inhibitory activit

169 These results suggest that factors in breast milk may enhance the early immunomodulatory effec

170 gically active allergens transferred through breast milk may prevent instead of priming allergic sens

171 veal unique mechanisms through which SIgA in breast milk may promote lifelong intestinal homeostasis,

172 nt formula so it is closer to that of mature breast milk may reduce long-term risk of overweight or o

173 ive total enteral feeding volume provided as breast milk: median (IQR) proportion of breast milk, 92%

174 Despite daily exposure to virus in breast milk, most infants breastfed by HIV-positive wome

175 in paired human maternal serum (n = 102) and breast milk (n = 105) collected in 2008-2009 in the Sher

176 d on protein and fat content of administered breast milk (n = 15).

177 ier adding 1.8 g of bovine protein/100 mL of breast milk [n = 15]) or individualized high-protein sup

178 Finally, human breast milk obtained before or after peanut ingestion wa

179 luate the in vivo HIV-inhibitory activity of breast milk obtained from HIV-positive transmitting and

180 measured in plasma, cervical secretions, and breast milk of 147 HIV-1-infected women to define correl

181 between levels of n-3 PUFAs and n-6 PUFAs in breast milk of allergic- and nonallergic mothers and ast

182 nance of IgG isotype Env-specific B cells in breast milk of chronically HIV-infected women.

183 alovirus (HCMV)-specific T-cell responses in breast milk of HCMV-seropositive mothers is not well def

184 s low, suggesting that immune factors in the breast milk of HIV-1-infected mothers help to limit tran

185 This suggests that immune factors in breast milk of HIV-1-infected mothers help to limit vert

186 ompared the antibody responses in plasma and breast milk of HIV-1-transmitting and -nontransmitting m

187 Breast milk of HIV-negative women can inhibit HIV infect

188 It is well documented that breast milk of HIV-negative women can inhibit HIV infect

189 re, we demonstrate, for the first time, that breast milk of HIV-positive mothers (nontransmitters and

190 Our results demonstrate that breast milk of HIV-positive mothers has potent HIV-inhib

191 bird eggs, fish, dolphin blubber, and in the breast milk of humans that consume seafood.

192 The aim of our study was to discern whether breast milk of ITP mothers contained antiplatelet antibo

193 he potential transfer of medication into the breast milk of nursing mothers may limit which antirheum

194 edians (IQRs) of infant daily intake through breast milk of vitamin D and 25(OH)D were 0.10 mug (0.02

195 Breast milk oligosaccharides shape the intestinal enviro

196 that in most current formulas and closer to breast milk) on infant growth by comparing against WHO g

197 ot differ by feeding mode (predominantly fed breast milk or not).

198 tion of other foods or drinks in addition to breast-milk or replacement-milk substitutes before 4-6 w

199 Non-breast milk oral water intake did not differ by group (P

200 Predictions of breast milk PBDE concentration were consistent with repo

201 ervational study, we investigated plasma and breast milk pharmacokinetics of efavirenz and breastfed

202 its safety requires an understanding of its breast milk pharmacokinetics, level of breastfed infants

203 icient evidence to suggest that colostrum or breast milk polyunsaturated fatty acids influence the ri

204 intakes of total (complementary feeding plus breast milk) protein were 2.9 +/- 0.6 and 1.4 +/- 0.4 g

205 g body of evidence, the associations between breast milk PUFA and allergic disease have not previousl

206 o exclusive soy formula, cow milk formula or breast milk regimens.

207 variety of clinical specimens (blood, urine, breast milk, respiratory samples, biopsies, and vitreous

208 Early exposure to SIgA in breast milk resulted in a pattern of intestinal epitheli

209 ld's age of 3 months, 276 mothers provided a breast milk sample.

210 PFOS was found in 13 out of 49 breast milk samples (0.76+/-1.27 ng/g), while PFOA was d

211 ed method showed the presence of caffeine in breast milk samples (12-179ng/mL).

212 sured lead in 81 maternal blood, plasma, and breast milk samples at 1 month postpartum and in 60 infa

213 These parabens were also measured in breast milk samples collected at approximately 3 months

214 The TFA content in 639 breast milk samples collected in 2009, 2010, and 2011 fr

215 rum samples and in 118 three-month expressed breast milk samples from mothers of children enrolled in

216 Breast milk samples had >50% detection for MP, PP, and E

217 Breast milk samples obtained at 3 months postpartum were

218 ing activity in sera of infants and serum or breast milk samples of mothers were measured using enzym

219 e complexes, and the IgE binding capacity of breast milk samples were measured using specific immunoa

220 Peak blood and breast milk samples were obtained 1-2 h after the matern

221 Breast milk samples were obtained from Kenyan mothers at

222 Maternal serum and breast milk samples were obtained prior to administratio

223 etermine whether viral DNA was encapsidated, breast milk samples were treated with DNAse before DNA e

224 supplemented infant formulas and three human breast milk samples were used to apply alumina hollow fi

225 A total of 75 women provided breast-milk samples (44 women provided breast-milk sampl

226 vided breast-milk samples (44 women provided breast-milk samples at both 2 wk and 2 mo postpartum).

227 o were breastfeeding were invited to provide breast-milk samples for VDA measurement [concentration o

228 Breast-milk samples were obtained from women who were en

229 ; the drug was not detected in any of the 10 breast-milk samples.

230 his study indicate that bacteria in mother's breast milk seed the infant gut, underscoring the import

231 r uninfected infants, we measured plasma and breast-milk selenium concentrations at 2 or 6 (depending

232 a selenium concentrations increased, whereas breast-milk selenium concentrations declined (14.3 +/- 1

233 etroviral drugs (ARV) on maternal plasma and breast-milk selenium concentrations.

234 associated with a change in their plasma or breast-milk selenium concentrations.

235 sociated with a change in maternal plasma or breast-milk selenium from 2 or 6 to 24 wk postpartum (bo

236 sociated with changes in maternal plasma and breast-milk selenium, but maternal selenium concentratio

237 el of asthma, oral exposure to Der p through breast milk strongly promotes sensitization rather than

238 first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyz

239 However, postnatal characteristics (e.g., breast milk substitutes, infection rates, underweight, a

240 xposed peripheral blood mononuclear cells to breast milk supernatant, which resulted in the generatio

241 Breast milk supplies the first source of antigen-specifi

242 content that more closely resembles that of breast milk supports healthy growth comparable to the WH

243 t Research on Environmental Chemicals) study.Breast-milk tetrahydrofolate (THF), 5-methyl-THF, 5-form

244 nsidered variation in specific components of breast milk that may affect early development.

245 Secondary outcomes, breast milk thiamine concentration and infant eTDP, were

246 ancy and early lactation had higher eTDP and breast milk thiamine concentrations and their infants ha

247 ctating women and newborn infants and higher breast milk thiamine concentrations compared with a cont

248 bsorb oral thiamine, with sharp increases in breast milk thiamine concentrations, but their breastfed

249 Low maternal thiamine intake reduces breast milk thiamine concentrations, placing breastfed i

250 tein (adding 1 g of bovine protein/100 mL of breast milk through a commercial human milk fortifier; n

251 for the regulation of nutritional status of breast milk through intestinal HIF-2alpha.

252 iately after birth and, ideally, continue on breast milk throughout the hospital stay.

253 ionships between maternal blood, plasma, and breast milk to better understand lactational transfer of

254 ition from passively acquired IgA present in breast milk to host-derived IgA.

255 However, administration of human breast milk to young mice, notably before weaning, does

256 dologies demonstrated that the magnitudes of breast milk total and secretory IgA responses against a

257 Breast milk total thiamine concentrations were 14.4 mug/

258 containing supplement.We sought to determine breast-milk total folate and unmetabolized folic acid (U

259 Breast-milk total folate was 18% higher (P < 0.001) in s

260 ment use was associated with modestly higher breast-milk total folate.

261 Breast milk transmission is responsible for almost half

262 l study of 307 infants evaluated the rate of breast milk transmission of NVP-resistant HIV and the co

263 Detectable breast-milk UMFA was nearly ubiquitous, including in wom

264 Breast-milk UMFA was proportionally higher than 5-methyl

265 Food allergens have been evidenced in breast milk under physiological conditions, but the kine

266 Changes in plasma and breast milk VA, BC, and CX were measured.

267 The phenotype of exosomes in breast milk varies with maternal sensitization and lifes

268 A linear mixed model was used to compare breast-milk VDA between the 3 study groups.

269 itamin D supplementation during pregnancy on breast-milk VDA in the first 2 mo of lactation.

270 Two studies investigating GE of breast milk versus formula indicated a faster GE for bre

271 , we observed a positive correlation between breast milk viral load and the CD8 pp65-specific respons

272 pment, and delivery mode and feeding method (breast milk vs formula) are determinants of its composit

273 estimated maximum infant efavirenz dose from breast milk was 809 microg/kg/day (215-2760) and pediatr

274 Breast milk was collected from 22 mothers at day 3-8 and

275 Breast milk was collected from 537 women recruited withi

276 Human breast milk was collected from two non-atopic peanut-tol

277 resistant, suggesting that the viral DNA in breast milk was encapsidated.

278 n) on the volatile compound profile of human breast milk was evaluated, in order to compare both pres

279 s were breast-fed, and in 10 of these cases, breast milk was examined for the presence of eculizumab;

280 oid cell lines, indicating that the virus in breast milk was infectious.

281 entional formula (control, n = 117) whenever breast milk was not available during the first 6-8 month

282 in these families, although specific IgA in breast milk was not proportionally up-regulated.

283 ing (NAT) of transfused blood components and breast milk was performed to identify sources of CMV tra

284 uoroalkyl substance (PFAS) concentrations in breast milk, we measured perfluorooctane sulfonic (PFOS)

285 n (IQR) time-averaged peak concentrations in breast milk were 3.2 ng/mL (2.3 to 4.7) for tenofovir an

286 (IQR) time-averaged trough concentrations in breast milk were 3.3 ng/mL (2.3 to 4.4) for tenofovir an

287 age; intakes from complementary feeding and breast milk were assessed at 9 mo of age.

288 Early enteral feeding and, in particular, breast milk were correlated with an increase in lactate-

289 ngly, compared with formula, human and mouse breast milk were enriched in sodium nitrate--a precursor

290 -elicited Env-specific B cells isolated from breast milk were IgA isotype, in stark contrast to the o

291 However HIV-1 levels within the cervix and breast milk were not associated with CMV within these co

292 Overall, PBDE exposures via breast milk were not associated with early-life anthropo

293 No adverse effects of AED exposure via breast milk were observed at age 6 years, consistent wit

294 ak and trough samples of maternal plasma and breast milk were obtained at drug concentration steady s

295 The factors in breast milk which influence these processes are still un

296 tus in mothers modulates TRAIL expression in breast milk, which may have implications for both mother

297 of n-3 and n-6 PUFA levels in colostrum and breast milk with allergic disease and lung function at a

298 nt in children of allergic mothers receiving breast milk with higher levels of n-3 long chain polyuns

299 in children of nonallergic mothers receiving breast milk with higher levels of n-6LCP (OR 1.86; 95% C

300 a-inhibitors have little to no transfer into breast milk, with negligible levels measured in infant s